Equity Research Subscription: When the Fee Pays for Itself

The trial ends next week, and the renewal screen wants an annual fee. Should you pay it? An equity research subscription pays for itself only when its cost is a minor part of the money the research actually guides and reading it changes what you buy, sell, size or skip. Work out the fee as a percent of that money first. When it is a large slice, no quality of analysis makes up for it, and the decision is made before you read a single report. Then test whether the research changes anything.

The fee as a share of the account

Call the annual fee F. Put it against hypothetical accounts of different sizes.

That percentage is the extra return the research must add each year to break even. Few would bet on ten points a year. Two points is a stiff hurdle. Half a point is a bar that good research has a fair chance of clearing, provided you act on it and the advice holds up over more than a single lucky year.

The largest account can hide the same problem. Say the 200F account holds 160F in index funds and 40F in stocks. The research covers stocks. It does nothing for the funds. The fee is really spread over the 40F it can influence.

Run the sum on the part of your account the research touches. For a lot of investors with a core of funds and a handful of stock picks, the drag looks more like the 50F account’s than the 200F one’s, whatever the total balance says. Rerun the percentage at every renewal, with the fee you will actually be charged and the account as it stands then.

Time saved is the second test

Research can also pay in hours. If the reports replace work you would otherwise do yourself, such as reading filings, building models and checking estimates, the time has a value even when returns are no better.

Value your time above that figure and the hours alone cover the fee. The saving counts only if you would really have done the work. Someone who would have skipped the filings anyway saves nothing, and someone who spends an hour reading each report has to subtract that hour from the total before comparing it with the fee.

What the fee buys you

Research subscriptions sell a mix of material. Independent research is written by firms whose revenue comes from readers. Sell-side reports come from banks and brokers. They’re written for institutional clients and often reach individuals free through a brokerage account. Then there’s data, meaning estimates, screens, fair value figures and charts. Your free tools may already show a lot of it.

Check your brokerage before anything else. Free and paid ways to get analyst research reports covers where to look. If your broker already supplies reports on most of your holdings, the subscription has to beat free research, which is a much harder test than beating nothing. Then look at what is left. A service that adds only data you already have charges F for a duplicate.

The stock research subscription guide covers what to check on methodology, coverage and conflicts. Use it for the quality questions. Quality alone doesn’t settle anything, though. Even excellent research has to earn back F in an account your size.

The decision test on a trial

Before the trial starts, write down the decisions you are about to make. A stock you’re thinking of buying. A position you’re thinking of trimming. Watchlist names near a price that would make you act. Beside each, write your current leaning and the reason for it. Do it before you open a single report. Memory rewrites these things afterward, and every report starts to look as though it either changed your mind or confirmed what you had thought all along, whichever story flatters the research or you.

Then read the research on each one. Read the estimates and the risks along with the rating. Reading an analyst report in 15 minutes sets out an order for doing that. Where a report gives a fair value, compare its growth and discount rate assumptions with your own, or with a quick model built the way estimating fair value with a DCF describes, since a fair value is only as good as the inputs behind it.

At the end of the trial, go back to the list. Did any leaning change? A buy postponed until after earnings counts. So does a smaller position. A risk you had missed counts too, even one that turned out to be sitting in the filings all along, because the research found it and you had not.

The catch is the counterfactual. You never find out for certain what would have happened, and a decision the research changed for the worse counts against it just as heavily as the good ones count for it. Keep the list going after you subscribe, and score it once a year.

If nothing on the list changed, the research agreed with you. That’s reassurance. Some people will pay for that, and it’s a fair thing to want, but it’s a weak reason to renew at a fee that eats two points a year.

Where the arithmetic stops

Learning is the exception. Early on, reading professional research teaches you how analysts build a case, what they check and where they cut corners, and that education can be worth more than any single decision it changes. Call it tuition. Give it a budget and an end date. After that, switch to the decision test.

Very large accounts are the opposite case. On an account worth 1,000F the fee is a tenth of a percent, small enough that the drag hardly registers, and the only question left is whether you will read what you pay for.

The other limit is behavior. Research that pushes you to trade more costs commissions, spreads and taxes that never show up in the fee, so a subscription that passes the fee and decision tests on paper can still lose money if it turns a patient investor into a busy one. Watch your turnover in the months after you sign up.